Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
IDXX's Cash-to-Debt is ranked lower than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. IDXX: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
IDXX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 5.03 Max: 240.89
Current: 0.33
0.29
240.89
Equity-to-Asset -0.07
IDXX's Equity-to-Asset is ranked lower than
91% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. IDXX: -0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
IDXX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07  Med: 0.69 Max: 0.82
Current: -0.07
-0.07
0.82
Interest Coverage 10.93
IDXX's Interest Coverage is ranked lower than
66% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. IDXX: 10.93 )
Ranked among companies with meaningful Interest Coverage only.
IDXX' s Interest Coverage Range Over the Past 10 Years
Min: 10.26  Med: 43.56 Max: 91.84
Current: 10.93
10.26
91.84
Piotroski F-Score: 7
Altman Z-Score: 7.30
Beneish M-Score: -2.75
WACC vs ROIC
5.26%
32.02%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 19.73
IDXX's Operating Margin % is ranked higher than
89% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. IDXX: 19.73 )
Ranked among companies with meaningful Operating Margin % only.
IDXX' s Operating Margin % Range Over the Past 10 Years
Min: 14.76  Med: 18.6 Max: 20.3
Current: 19.73
14.76
20.3
Net Margin % 12.51
IDXX's Net Margin % is ranked higher than
87% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. IDXX: 12.51 )
Ranked among companies with meaningful Net Margin % only.
IDXX' s Net Margin % Range Over the Past 10 Years
Min: 10.19  Med: 12.38 Max: 13.78
Current: 12.51
10.19
13.78
ROA % 14.85
IDXX's ROA % is ranked higher than
90% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. IDXX: 14.85 )
Ranked among companies with meaningful ROA % only.
IDXX' s ROA % Range Over the Past 10 Years
Min: 13.44  Med: 15.68 Max: 16.78
Current: 14.85
13.44
16.78
ROC (Joel Greenblatt) % 67.85
IDXX's ROC (Joel Greenblatt) % is ranked higher than
86% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. IDXX: 67.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IDXX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.83  Med: 62.77 Max: 69.67
Current: 67.85
53.83
69.67
3-Year Revenue Growth Rate 15.30
IDXX's 3-Year Revenue Growth Rate is ranked higher than
82% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. IDXX: 15.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IDXX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.4  Med: 11.8 Max: 23.1
Current: 15.3
8.4
23.1
3-Year EBITDA Growth Rate 16.70
IDXX's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. IDXX: 16.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IDXX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 8.7  Med: 15.1 Max: 96.9
Current: 16.7
8.7
96.9
3-Year EPS without NRI Growth Rate 11.90
IDXX's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. IDXX: 11.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IDXX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 8.8  Med: 16 Max: 26.1
Current: 11.9
8.8
26.1
GuruFocus has detected 4 Warning Signs with IDEXX Laboratories Inc $IDXX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IDXX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IDXX Guru Trades in Q1 2016

Columbia Wanger 1,049,000 sh (New)
Jim Simons 437,504 sh (+242.60%)
Mairs and Power 3,998 sh (unchged)
Chris Davis Sold Out
Ron Baron 6,603,503 sh (-4.18%)
Ruane Cunniff 7,668,176 sh (-4.47%)
Chuck Royce 882,612 sh (-26.92%)
» More
Q2 2016

IDXX Guru Trades in Q2 2016

Paul Tudor Jones 5,712 sh (New)
Jim Simons 537,404 sh (+22.83%)
Mairs and Power 3,998 sh (unchged)
Ron Baron 6,584,973 sh (-0.28%)
Chuck Royce 863,812 sh (-2.13%)
Columbia Wanger 370,439 sh (-64.69%)
Ruane Cunniff 107,894 sh (-98.59%)
» More
Q3 2016

IDXX Guru Trades in Q3 2016

Jim Simons 694,304 sh (+29.20%)
Mairs and Power 3,998 sh (unchged)
Ruane Cunniff 106,944 sh (-0.88%)
Ron Baron 6,500,206 sh (-1.29%)
Chuck Royce 708,990 sh (-17.92%)
Paul Tudor Jones 4,599 sh (-19.49%)
Columbia Wanger 224,612 sh (-39.37%)
» More
Q4 2016

IDXX Guru Trades in Q4 2016

Mairs and Power 3,998 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 613,200 sh (-11.68%)
Ron Baron 5,690,887 sh (-12.45%)
Columbia Wanger 183,232 sh (-18.42%)
Chuck Royce 382,900 sh (-45.99%)
Ruane Cunniff 27,741 sh (-74.06%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2835
Compare:NYSE:DGX, OTCPK:SSMXY, NYSE:LH, NYSE:A, NYSE:Q, NAS:DXCM, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO.B, OTCPK:SUVPF, NAS:ICLR, NYSE:CRL, NAS:CPHD, NAS:PRAH, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL » details
Traded in other countries:IX1.Germany,
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for the veterinary, bioresearch, water, livestock, poultry and dairy markets.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, laboratory equipment for blood-panel analysis, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 42% of its revenue from outside the United States.

Guru Investment Theses on IDEXX Laboratories Inc

Ron Baron Comments on IDEXX Laboratories Inc. - Nov 14, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased in the third quarter. The stock continued to rally on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We believe that IDEXX’s direct go-to-market model coupled with research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg)



From Ron Baron (Trades, Portfolio)'s Barons Partners Fund third-quarter 2016 commentary.

Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Oct 21, 2016

Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased after the company reported impressive financial results, which led to a meaningful expansion in its trading multiple. We believe the company’s competitive position is strong and improving, as evidenced by its accelerating organic revenue growth, the robust placements of its diagnostic instruments into veterinary clinics, and the higher prices it is capturing across its product portfolio. In addition, IDEXX’s results demonstrated operating margin expansion, which is finally being recognized after several years of intensive investment into its business. Looking forward, we expect to witness sustained double-digit organic revenue growth during the next several years, driven by productivity benefits from its move to a direct sales model in the U.S., the company’s persistent innovation pipeline, and returns on its intensive investment into international markets.





From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Oct 11, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the leading provider of diagnostics to the veterinary industry. The company spends six times more on R&D annually than all its competitors combined. As a result, it has continuously improved its menu of diagnostics, which we believe is unsurpassed in the industry. IDEXX is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. The company’s products are sold via a razor/razorblade model, which produces high retention rates and incremental margins. We think that IDEXX’s direct go-to-market model coupled with meaningful R&D-driven product enhancements will continue to boost revenue and earnings growth over time.



From Baron Funds' fall 2016 newsletter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Aug 17, 2016

IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders.





From Baron Funds' Small Cap Fund second quarter 2016 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jul 25, 2016

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years.



Baron Asset Fund second quarter shareholder letter.



Check out Ron Baron latest stock trades

Ruane Cunniff Comments on Idexx Laboratories - Jul 13, 2016

We made the difficult decision during the quarter to part with our longtime holding in Idexx Laboratories (NASDAQ:IDXX). Idexx had been a wonderful stock for us over the past 13 years, compounding at better than a 17% rate from the time of our original purchases in 2003 through June 30. This compares to a 7.4% compound for the S&P 500 Index over the same period. Idexx has a terrific market position in veterinary diagnostics and a very capable CEO in Jon Ayers. But the market fully realizes Idexx’s strengths. It is according Idexx a price-to- earnings ratio of more than 40x the 2016 consensus earnings per share estimate of $ 2.21. The company has grown earnings per share at an 11% rate for the past five years and should grow a bit below that rate in 2016. The market helped with our decision as the price of Idexx shares rose sharply during the quarter. We owe a huge debt of gratitude to Jon Ayers. He is a hero to Sequoia shareholders and greatly respected by all of us.



From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Apr 26, 2016

Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Jan 14, 2016

Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leader in veterinary diagnostics. The company is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. It has had much success placing its proprietary testing instrument in clinics, and has a deep pipeline of tests and products. Its razor/razorblade model results in high retention rates and incremental margins. IDEXX is transitioning to all-direct distribution, which we expect will further enhance margins and future growth.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Nov 04, 2015

Shares of veterinary diagnostics manufacturer IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to the third quarter performance. The company reported strong second quarter results that demonstrated share gains in instruments and reference labs, and assuaged concerns regarding its competitive position in rapid assays. Catalyst placements grew 44% in the quarter, driven by the launch of CatalystOne in the U.S. and Europe. Premium hematology placements grew 30% in the third quarter, a meaningful increase from 14% in the second quarter. Reference lab results were also strong, growing 12.1% in the third quarter. (Neal Rosenberg)



From Baron Funds' Baron Partners Fund shareholder letter for Q3 2015.



Check out Ron Baron latest stock trades

Sequoia Fund Comments on Idexx - Aug 28, 2015

Arman Kline:



The company had a wonderful 2014. It made a big decision to go to direct distribution. Historically, Idexx (NASDAQ:IDXX) distributed the consumables for its instruments and its rapid assay tests for companion animals through a network of distributors in the US. Overseas it was a little bit more direct. It made a decision to go direct here, and the reason it made that decision is that it felt as the market leader with a dominant market share introducing new technology, new products, it needed a sales force that could encourage the adoption of those products more than it needed the help of distributors to penetrate the market. We think that management made the right decision.



Earlier this year, you may have noticed in the first quarter, Idexx had a little bit of a hiccup as a result of that move to direct distribution. A competitor came out with a lower priced product and distributors picked it up because Idexx was no longer selling through them. The competitor was very aggressive, and, as the CEO of Idexx said, there is now a rapid assay price war going on in the industry. The business is still growing very nicely, but the stock was priced for perfection — last year it was trading for a high 30s multiple of forward earnings. Most of you have probably noticed we have sold down our position as a result of that valuation. We are still large shareholders. We still believe in the business. We think it is unique. We think it has a long runway. We think it will continue to dominate that space. We remain excited about the future there and believe in its direct distribution model. Do you want to add anything, Greg?



Greg Steinmetz:



Idexx is responsible for at least 75% if not more of all of the R&D spending in veterinary diagnostics. It can earn a nice return on that because this megatrend of the humanization of pets is showing no signs of stopping. People will spend anything on their animal if the veterinarian gives them a credible reason why they should. And it is a lot more than just rich people. It is a broad swath of pet owners. Idexx, to its credit, is a great believer in veterinary diagnostics. Management sees it as a very long-lived opportunity. It has really been paying off. Despite the issue with rapid assay this year, we are still going to get 10% organic growth. International is going gangbusters, and there the humanization of pets is just getting started. Even in China — where they are boiling Tibetan mastiffs, if you read the story in the Times two weeks ago — people are starting to treat animals more like humans. It is an opportunity that Idexx is going to benefit a great deal from.



From Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II - Sequoia Fund.



Check out Ruane Cunniff latest stock trades

Baron Funds Comments on IDEXX Laboratories Inc. - Aug 18, 2015

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics, detracted from performance after outperforming meaningfully during recent periods. We attribute a portion of the stock’s decline to greater-than-expected foreign exchange headwinds. Separately, the company noted increased competition and lower prices in a sub-segment of its product portfolio, which we estimate accounts for just 3% of total revenue. We believe this enhanced competition stems from the company’s recent transition to a direct sales strategy in the U.S., and we are optimistic that management will successfully react with pricing programs to better serve these customers in the future. We expect accelerating organic revenue growth over the next several years, driven by productivity benefits from its new domestic sales strategy, additional products, and ongoing success in international markets. We believe that faster top line growth should lead to accelerated margin expansion, creating a virtuous cycle of earnings growth, reinvestment, and returns of capital to shareholders.



From Baron Funds' second quarter commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about IDEXX Laboratories Inc

Ron Baron Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased in the third quarter. The stock continued to rally on strong financial results and multiple expansion. Competitive trends are strong and improving, highlighted by instrument revenue growth, domestic lab growth, rising sales productivity, and stability in rapid assays. We believe that IDEXX’s direct go-to-market model coupled with research and development-driven product enhancements will put steady upward pressure on organic revenue and earnings growth over time. (Neal Rosenberg) Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) increased after the company reported impressive financial results, which led to a meaningful expansion in its trading multiple. We believe the company’s competitive position is strong and improving, as evidenced by its accelerating organic revenue growth, the robust placements of its diagnostic instruments into veterinary clinics, and the higher prices it is capturing across its product portfolio. In addition, IDEXX’s results demonstrated operating margin expansion, which is finally being recognized after several years of intensive investment into its business. Looking forward, we expect to witness sustained double-digit organic revenue growth during the next several years, driven by productivity benefits from its move to a direct sales model in the U.S., the company’s persistent innovation pipeline, and returns on its intensive investment into international markets. Read more...
Baron Funds Comments on IDEXX Laboratories Guru stock highlight
Top 10 holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) is the leading provider of diagnostics to the veterinary industry. The company spends six times more on R&D annually than all its competitors combined. As a result, it has continuously improved its menu of diagnostics, which we believe is unsurpassed in the industry. IDEXX is benefiting from secular growth spending on pets, driven by favorable demographics, increased use of diagnostics, and an increasing focus on preventative care. The company’s products are sold via a razor/razorblade model, which produces high retention rates and incremental margins. We think that IDEXX’s direct go-to-market model coupled with meaningful R&D-driven product enhancements will continue to boost revenue and earnings growth over time. Read more...
Baron Funds Comments on IDEXX Laboratories Guru stock highlight
IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading company in veterinary diagnostics, rallied in the second quarter after reporting strong financial results. Organic revenue growth was up 11%, driven by instrument revenue gains of 16% (and new placements up 25%), consumables’ sales up 12%, and reference labs sales up 15%. The company’s efforts to build a direct sales force and introduce new innovative products are showing terrific results. We expect revenue growth to accelerate as additional tests gain traction and the productivity of the new salesforce continues to improve. The company remained aggressive with its share repurchase program. We applaud the company’s plan to take on some leverage to buy in shares, especially as they bought at the lows, and since we believe the business is so stable and annuity-like that the balance sheet should have a reasonable amount of debt to optimize equity returns for the shareholders. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported another quarter of strong financial results. We continue to believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 25% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories continued to grow at more than twice the rate of its main competitor. We believe that these trends, coupled with the revenue contributions from its new proprietary tests, has potential for better revenue and earnings growth during the next few years. Read more...
Ruane Cunniff Comments on Idexx Laboratories Guru stock highlight
We made the difficult decision during the quarter to part with our longtime holding in Idexx Laboratories (NASDAQ:IDXX). Idexx had been a wonderful stock for us over the past 13 years, compounding at better than a 17% rate from the time of our original purchases in 2003 through June 30. This compares to a 7.4% compound for the S&P 500 Index over the same period. Idexx has a terrific market position in veterinary diagnostics and a very capable CEO in Jon Ayers. But the market fully realizes Idexx’s strengths. It is according Idexx a price-to- earnings ratio of more than 40x the 2016 consensus earnings per share estimate of $ 2.21. The company has grown earnings per share at an 11% rate for the past five years and should grow a bit below that rate in 2016. The market helped with our decision as the price of Idexx shares rose sharply during the quarter. We owe a huge debt of gratitude to Jon Ayers. He is a hero to Sequoia shareholders and greatly respected by all of us. Read more...
Baron Funds Comments on IDEXX Laboratories Inc. Guru stock highlight
Shares IDEXX Laboratories, Inc. (NASDAQ:IDXX), the leading provider of testing and diagnostics to veterinarians, gained after the company reported healthy financial results. We believe that IDEXX’s business trends are improving and that its competitive position is becoming increasingly unassailable. The company’s placements of new diagnostic instruments in veterinary hospitals grew by almost 50% in its recent quarter. We expect this to be a key driver of future growth because these instruments require the ongoing purchase of high-margin consumables to perform in-clinic tests. In addition, the company’s network of domestic testing laboratories grew at more than twice the rate of its main competitor. We also observed rising productivity of its field salesforce, and a rebound in its rapid assay products. We believe that these trends, coupled with a number of new tests that should emerge from its meaningful research and development effort, will drive increased organic revenue and earnings growth during the next few years. Read more...

Ratios

vs
industry
vs
history
PE Ratio 63.11
IDXX's PE Ratio is ranked lower than
84% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. IDXX: 63.11 )
Ranked among companies with meaningful PE Ratio only.
IDXX' s PE Ratio Range Over the Past 10 Years
Min: 15.18  Med: 31.09 Max: 63.26
Current: 63.11
15.18
63.26
Forward PE Ratio 52.08
IDXX's Forward PE Ratio is ranked lower than
89% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 52.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 63.11
IDXX's PE Ratio without NRI is ranked lower than
84% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. IDXX: 63.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
IDXX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.02  Med: 30.92 Max: 63.26
Current: 63.11
15.02
63.26
Price-to-Owner-Earnings 57.00
IDXX's Price-to-Owner-Earnings is ranked lower than
82% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. IDXX: 57.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IDXX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.36  Med: 34.84 Max: 73.8
Current: 57
21.36
73.8
PS Ratio 7.90
IDXX's PS Ratio is ranked lower than
75% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. IDXX: 7.90 )
Ranked among companies with meaningful PS Ratio only.
IDXX' s PS Ratio Range Over the Past 10 Years
Min: 1.75  Med: 4.02 Max: 7.91
Current: 7.9
1.75
7.91
Price-to-Free-Cash-Flow 51.89
IDXX's Price-to-Free-Cash-Flow is ranked lower than
76% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. IDXX: 51.89 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IDXX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.03  Med: 34.54 Max: 85.16
Current: 51.89
13.03
85.16
Price-to-Operating-Cash-Flow 41.84
IDXX's Price-to-Operating-Cash-Flow is ranked lower than
81% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. IDXX: 41.84 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IDXX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.44  Med: 24.51 Max: 44.83
Current: 41.84
11.44
44.83
EV-to-EBIT 40.56
IDXX's EV-to-EBIT is ranked lower than
84% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. IDXX: 40.56 )
Ranked among companies with meaningful EV-to-EBIT only.
IDXX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.5  Med: 21.4 Max: 41.8
Current: 40.56
10.5
41.8
EV-to-EBITDA 33.20
IDXX's EV-to-EBITDA is ranked lower than
89% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. IDXX: 33.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
IDXX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.3  Med: 17.4 Max: 34.2
Current: 33.2
8.3
34.2
PEG Ratio 4.74
IDXX's PEG Ratio is ranked lower than
72% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. IDXX: 4.74 )
Ranked among companies with meaningful PEG Ratio only.
IDXX' s PEG Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.13 Max: 5.03
Current: 4.74
0.77
5.03
Shiller PE Ratio 98.49
IDXX's Shiller PE Ratio is ranked lower than
90% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. IDXX: 98.49 )
Ranked among companies with meaningful Shiller PE Ratio only.
IDXX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 26.11  Med: 50.4 Max: 98.75
Current: 98.49
26.11
98.75
Current Ratio 0.90
IDXX's Current Ratio is ranked lower than
89% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. IDXX: 0.90 )
Ranked among companies with meaningful Current Ratio only.
IDXX' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.02 Max: 4.1
Current: 0.9
0.9
4.1
Quick Ratio 0.74
IDXX's Quick Ratio is ranked lower than
88% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. IDXX: 0.74 )
Ranked among companies with meaningful Quick Ratio only.
IDXX' s Quick Ratio Range Over the Past 10 Years
Min: 0.73  Med: 1.41 Max: 3.03
Current: 0.74
0.73
3.03
Days Inventory 79.83
IDXX's Days Inventory is ranked lower than
51% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. IDXX: 79.83 )
Ranked among companies with meaningful Days Inventory only.
IDXX' s Days Inventory Range Over the Past 10 Years
Min: 77.45  Med: 81.19 Max: 89.55
Current: 79.83
77.45
89.55
Days Sales Outstanding 42.04
IDXX's Days Sales Outstanding is ranked higher than
76% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. IDXX: 42.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
IDXX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.43  Med: 41.31 Max: 42.91
Current: 42.04
37.43
42.91
Days Payable 27.40
IDXX's Days Payable is ranked lower than
82% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. IDXX: 27.40 )
Ranked among companies with meaningful Days Payable only.
IDXX' s Days Payable Range Over the Past 10 Years
Min: 13.82  Med: 22.5 Max: 27.4
Current: 27.4
13.82
27.4

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 4.50
IDXX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. IDXX: 4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IDXX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.4  Med: 2.7 Max: 6.2
Current: 4.5
-1.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.53
IDXX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. IDXX: 5.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IDXX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.14  Med: 2.4 Max: 5.54
Current: 5.53
1.14
5.54
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.47
IDXX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
90% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.85 vs. IDXX: 3.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.96
IDXX's Price-to-Median-PS-Value is ranked lower than
88% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. IDXX: 1.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IDXX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 0.89 Max: 1.97
Current: 1.96
0.45
1.97
Price-to-Peter-Lynch-Fair-Value 5.04
IDXX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
94% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. IDXX: 5.04 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IDXX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.88 Max: 5.05
Current: 5.04
0.96
5.05
Earnings Yield (Greenblatt) % 2.46
IDXX's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. IDXX: 2.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IDXX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 4.7 Max: 9.5
Current: 2.46
2.4
9.5
Forward Rate of Return (Yacktman) % 13.70
IDXX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. IDXX: 13.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IDXX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.7  Med: 16.6 Max: 22.4
Current: 13.7
12.7
22.4

More Statistics

Revenue (TTM) (Mil) $1,775
EPS (TTM) $ 2.44
Beta0.42
Short Percentage of Float3.66%
52-Week Range $75.03 - 154.57
Shares Outstanding (Mil)87.92

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,922 2,101
EPS ($) 2.95 3.40
EPS without NRI ($) 2.95 3.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.59%
Dividends per Share ($)
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
7 Stocks With Great 12-Month Performances Feb 24 2017 
Beat the Market With a Water ETF Feb 23 2017 
High Predictability Stocks: Western Union, FMC Tech Jan 25 2017 
WOOF: Health Care Without the Drama Dec 12 2016 
Ron Baron Comments on IDEXX Laboratories Inc. Nov 14 2016 
Baron Partners Fund 3rd Quarter Commentary Nov 14 2016 
Baron Funds Comments on IDEXX Laboratories Inc. Oct 21 2016 
Baron Asset Fund 3rd Quarter Shareholder Letter Oct 20 2016 
Baron Funds Comments on IDEXX Laboratories Oct 11 2016 
Baron Fund's Fall Newsletter: A High Conviction Approach to Investing Oct 11 2016 

More From Other Websites
Maine-based Idexx Laboratories joins NASDAQ-100 Index Mar 20 2017
Maine-based Idexx Laboratories joins NASDAQ-100 Index Mar 20 2017
IDEXX Laboratories Joins the NASDAQ-100 Index Mar 20 2017
3 Medical Device Stocks to Brave Policy Uncertainty Mar 16 2017
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations Mar 15 2017
ABIOMED Impella Heart Pump Reduces Kidney Injury during PCI Mar 13 2017
IDEXX Laboratories, Inc. to Join the NASDAQ-100 Index Beginning March 20, 2017 Mar 10 2017
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain Mar 09 2017
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest Mar 08 2017
IDEXX (IDXX) Up 5.8% Since Earnings Report: Can It Continue? Mar 07 2017
Idexx Laboratories: Why I'm Avoiding This Puppy Mar 03 2017
IDEXX Laboratories to Present at Raymond James Institutional Investors Conference Feb 27 2017
Beat the Market With a Water ETF Feb 23 2017
IDEXX LABORATORIES INC /DE Financials Feb 23 2017
IDEXX LABORATORIES INC /DE Files SEC form 8-K/A, Change in Directors or Principal Officers Feb 22 2017
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Change in Directors or Principal Officers Feb 21 2017
IDEXX LABORATORIES INC /DE Files SEC form 10-K, Annual Report Feb 17 2017
IDEXX LABORATORIES INC /DE Files SEC form 8-K/A, Change in Directors or Principal Officers Feb 16 2017
Top Ranked Momentum Stocks to Buy for February 14th Feb 14 2017
Can the Rally in IDEXX Laboratories (IDXX) Shares Continue? Feb 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)